Recently Released Market Study: Spain Pharmaceuticals & Healthcare Report Q2 2013
The sharp drop in public pharmaceutical expenditure in Spain during the second half of 2012 warns of a continuing fall in spending on medicines in 2013. BMI notes that this does not bode well for drugmakers selling their products in Spain. The success of the implemented policies may encourage the enforcement of further cost-containment measures, which, with the ongoing public hospital debt situation, seriously hampers the country's attractiveness as a location in which to sell drugs, despite its favourable demographic...
View full press release